Skip to main content
. 2015 Mar 25;6(12):10563–10576. doi: 10.18632/oncotarget.3384

Figure 6. iVR1 showed a synergic effect in combination with irinotecan.

Figure 6

(A), iVR1 (25 mg/kg, each other day) and irinotecan (50 mg/kg once at week) were delivered alone or in combination starting at day 5 from cell inoculation and for 24 days. TV was measured three times a week and data are represented as the mean ± SEM (N = 7). At day 21: *p < 0.005 for iVR1 and irinotecan compared to vehicle, §p < 0.0001 versus vehicle, #p < 0.005 vs iVR1 and irinotecan. (B), top, western blot analysis of VEGFR1 phosphorylation performed on mixed matching amounts of protein extracts belonging to the same experimental tumor group. Low, normalization with anti-VEGFR1 antibody performed on the same filter. The values of densitometry analyses are shown. Values (in percentages) were calculated as the ratio of degree of receptor phosphorylation with respect to the total receptor amounts. The value of 100 has been arbitrarily assigned to vehicle. (C), Kaplan-Meier survival curves of iVR1, irinorecan and bevacizumab (bevaciz, 5 mg/Kg two times a week) treatments, alone or in combination. Drugs were delivered as in A. Dashed line indicates 50% of survival. Bevaciz, irinotecan or iVR1 treatments were significantly lower compared to vehicle (p < 0.01) as well as the two combination treatments, iVR1 plus irinotecan and bevaciz plus irinotecan (p < 0.001).